Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Am Soc Nephrol
मुख्य लेखकों: Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Nephrology 2017
विषय:
Clinical Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576933/
https://ncbi.nlm.nih.gov/pubmed/28400446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111179
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन